Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Reardon, David
Item TypeName
Academic Article Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Academic Article Neurofibromatosis type 2.
Academic Article Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Academic Article Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
Academic Article Phase II study of GleevecĀ® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Academic Article Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Academic Article Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Academic Article Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Academic Article An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.
Academic Article Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas.
Academic Article Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma.
Academic Article A phase I dose escalation study of imatinib mesylate plus standard-dosed temozolomide in the treatment of patients with malignant glioma.
Academic Article Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results.
Academic Article Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea.
Academic Article Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG).
Search Criteria
  • Mesylates
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.